Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Qinghouyan is a Traditional Chinese Medicine (TCM) formulation developed by Shanghai Yusen New Drug Development Co., Ltd., specifically indicated for the treatment of acute pharyngitis. The drug is composed of several herbal extracts, including Radix Scrophulariae (Xuan Shen), Radix Ophiopogonis (Mai Dong), Radix Paeoniae Alba (Bai Shao), Semen Sterculiae Lychnophorae (Pang Da Hai), and Radix Glycyrrhizae (Gan Cao). Pharmacologically, Qinghouyan acts as an anti-inflammatory and analgesic agent by inhibiting the production of pro-inflammatory cytokines such as TNF-alpha and IL-6, and modulating inflammatory mediators like prostaglandins. It is designed to clear heat, detoxify, and moisten the throat, providing relief from symptoms such as pharyngeal pain, dryness, and congestion. The formulation has been approved and marketed in China, often produced by manufacturers like Zhejiang Conba Pharmaceutical.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Qinghouyan.